Previous studies determined the effectiveness of 6 months of therapy with eltrombopag in patients with ITP. In this analysis, researchers extended 4 clinical trials to assess efficacy and safety of eltrombopag therapy for more than 6 months in patients with ITP.
What is a CCDR clinical trial and how does it differ from clinical trials that test new drugs?
Two phase 3 studies reveal the clinical benefit, safety profile, and overall survival of nivolumab and docetaxel for patients with squamous and nonsquamous NSCLC.
Phase 1 trials are used to determine the safety profiles of treatment regimens. In this retrospective review, investigators sought to understand the reasons participants in these studies drop out.
Caregivers of patients with malignant brain tumors often bear additional burdens in their role, as these patients often experience cognition-related adverse effects as well as the effects of their cancer and its treatment.
Researchers have determined that, relative to differentiated tumor progeny or normal neuronal cells, ZIKV preferentially infects and kills GSCs.
The first interim analysis of the ENDEAVOR trial reported superiority of carfilzomib in some outcomes; however, data on overall survival were not available. This second interim analysis reports on overall survival with carfilzomib for patients with relapsed/refractory multiple myeloma.
Insurer approval rates rose from 85 percent before Affordable Care Act to 95 percent after the health care bill was enacted.
An analysis of rates at certain milestones in clinical trials of treatments for mNSCLC suggests these rates reflect end point results for immunotherapies vs targeted and conventional therapies.
Results of a phase 2 clinical trial of savolitinib, a highly selective small molecule inhibitor of c-Met, found the agent was active and tolerable in patients with Met-driven advanced or metastatic papillary renal cell carcinoma (PRCC).
Research on the effects of research demonstrated that oncology-related clinical trials provide measurable benefits in terms
Older adults are underrepresented in clinical trials of cancer drugs, according to study findings presented at the 2017 ASCO Annual Meeting.
Patients aged 80 years and older had a cancer incidence of 16% in 2013 yet made up only 4% of cancer drug clinical trial participants during 2005-2015.
IBM Watson for Clinical Trial Matching compares study enrollment criteria with patient data in electronic medical records.
Spherical Shape of New Drug Holds Promise for Bypassing the Blood Brain Barrier and Treating Aggressive Brain Cancer
An investigational drug with a novel spherical nucleic acid structure has the potential to cross the blood-brain barrier to treat glioblastoma multiforme.
Recent study results demonstrate that recombinant IL-11 with glucocorticoids is a safe and effective treatment for idiopathic thrombocytopenic purpura (ITP) in adults.
Survivors of primary brain tumors tend to freely discontinue cognitively engaging activities to compensate for diminishing cognitive function after treatment completion.
Temozolomide, an antimitotic chemotherapy used to treat brain cancer, demonstrated the potential to increase depression in a mouse model.
New data presented at the International Liver Congress 2017 suggest that nivolumab may produce long-term benefits in sorafenib-experienced patients with advanced HCC.
Deviation from radiation treatment protocol in young children being treated for brain neoplasms was associated with decreased overall survival.
Regular infusions of high doses of vitamin C safely increased cancer cell sensitivity to treatment in patients with brain and lung cancers.
Despite the ACA mandate on coverage for clinical trial participants, many facilities involved in cancer research still coping with insurance denials for participants.
NBTS launched a clinical trial finder specific to brain tumors to engage patients in research and clinical trials.
Prospective pilot study demonstrates accuracy of circulating tumor cells as a biomarker indicating lung cancer recurrence.
The addition of temozolomide to short-course radiotherapy in elderly patients with glioblastoma was associated with some survival benefit compared with radiotherapy alone.
Study identifies characteristics of clinical trials and barriers to patient accrual.
A recent analysis of tumor tissue samples from patients with glioblastoma and glial cancer indicate no association between CMV infection and brain cancer.
The researchers hope the results will lead to an increase in clinicians offering trials to their patients and an increase in women volunteering to participate in trials.
Video Based Personal Webpages (VBPWP) Can Be Used as a Compliment to Clinical Trial Patient Management
Clinical Trial Enrollment of Adolescent and Young Adult Patients With Cancer: A Systematic Review of the Literature and Proposed Solutions
[Clinical Oncology in Adolescents and Young Adults] This research evaluates methods that have been utilized in the clinical trial enrollment for adolescent and young adults with cancer.
Adding the anti-malaria drug chloroquine to standard therapies may help combat resistance to therapy and also resensitize glioblastoma patients to targeted treatments that had previously stopped working.
Although previous clinical trials have demonstrated that antiangiogenetic chemotherapy is not effective in GBM, researchers conducted a retrospective of review of perfusion MR images to determine if a phenotypic subtype of GBM may respond to antiangiogenic chemotherapy.
A new tool may show promise for improving clinical trial participation among black women with breast cancer, according to a study presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).
In a phase 1 clinical trial, the combination produces a significant and long-lasting response in patients with advanced disease including metastases to the peritoneum and lung.
In this study, researchers sought to improve the safety of panobinostat plus bortezomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma.
An analysis of data from caregivers and patients participating in a longitudinal study funded by the National Institutes of Health examines whether caregivers' anxiety, depressive symptoms, burden, and mastery influence survival for patients with newly diagnosed glioblastoma multiforme.
CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast Cancer
Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.
Questionnaires completed by patients with cancer considering enrollment in early-stage clinical trials indicate they may have unrealistic expectations.
Following the release of the Affordable Care Act (ACA) an increase in Hispanic women receiving breast cancer treatment and their related participation in clinical trials was observed.
Insurance status influences overall patient survival for some cancer types, but its impact on glioblastoma multiforme (GBM) survival is well documented. This research study explored the possible impact of insurance on GBM survival.
Despite the use of adjuvant chemotherapy, deferral of postoperative radiotherapy is associated with worse survival in pediatric patients with medulloblastoma.
Chimeric antigen receptor (CAR) T cells may have improved therapeutic potential when they have 2 targets, according to preclinical findings using a mouse model.
Cancer research relies of patients with cancer to participate in clinical trials. However, many patients cite various fears and misconceptions — some supported by physicians - as reasons for why they decline to participate in clinical trials.
Improved cancer detection and advances in treatment mean larger numbers of older cancer patients are becoming survivors, combined with demographic trends. But older patients are underrepresented in clinical trials.
Patients participating in early-phase clinical trials should be assessed for sleep quality, as poor sleep quality is associated with greater fatigue, symptom burden, and mood disturbance.
Benign brain tumors that have previously been associated with obesity and diabetes are surprisingly less likely to emerge in patients with high blood sugar, according to new research.
Although Drugs@FDA may be useful for validating trial primary outcomes found on ClinicalTrials.gov, Drugs@FDA lacked information on secondary outcomes and adverse events, including deaths, according to an analysis of data from 100 trials available on both websites.
Gross total resection to treat glioblastoma multiforme (GBM) showed progression-free survival benefits over subtotal resection and biopsy in a meta-analysis of 37 studies.
In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.
Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.
Outcomes in Clinical Trials Using Precision Medicine Demonstrate Effectiveness of Modality in Patients With Cancer
A meta-analysis of hundreds of cancer clinical trials revealed that therapeutic approaches using precision medicine had improved responses and longer disease remission, even in phase I trials.
US FDA standards demand that surrogate end points used in clinical trials be "reasonably likely to predict" survival for accelerated approval, or be established proxies for survival for traditional approval; however, surrogate end points used frequently lack formal study.
Daratumumab in Combination With Standard-of-Care Treatment Significantly Improves Outcomes in Patients With Multiple Myeloma
Daratumumab in combination with the standard-of-care treatment regimen reduced risk of disease progression or death by 63% compared with the standard-of-care regimen alone in patients with multiple myeloma who had received at least 1 prior line of therapy.
A third clinical trial is beginning for phase I testing of SurVaxM, a cancer vaccine. This trial tests for safety and effectiveness of the vaccine in combination with lenalidomide as maintenance therapy for adults with multiple myeloma.
Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical Trials
An international consortium devised an international prognostic index for chronic lymphocytic leukemia (CLL-IPI) that combines genetic, biochemical, and clinical parameters into a prognostic model to enable more targeted management of patients with CLL.
Physical exercise may have a direct effect on cancer that is as effective as drugs for treating patients with prostate cancer, even for those with advanced stages of the disease.
NETTER-1 trial results of the somatostatin analogue peptide, 177Lu-DOTA0-Tyr3-octreotate (177Lu-Dotatate), suggest a potential survival benefit in patients with advanced midgut neuroendocrine tumors (NETs), attendees at the ASCO 2016 Annual Meeting were told.
The role of antiangiogenic agents continues to evolve in the treatment of CNS cancers, attendees were told in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.
The 2016 WHO Classification of Infiltrating Gliomas alters diagnostic criteria, providing the basis for clinical trial inclusion or exclusion based on an integrated diagnosis and setting the stage for all future research, according to a summary of 4 posters related to CNS biomarkers presented at the ASCO 2016 Annual Meeting.
Patients whose treatment was based on the molecular characteristics of their particular tumor had significantly better outcomes compared with patients who did not.
Discovery might eventually lead to better treatment for glioblastoma multiforme
Only 40 percent of those polled had favorable view of these studies, but the number rose when they received more information.
Chemoradiotherapy Showed No Survival Benefit Over Chemotherapy in Locally Advanced Pancreatic Cancer
Researchers discovered no survival benefit of chemoradiotherapy over chemotherapy in treating locally advanced pancreatic cancer in the LAP01 Randomized Clinical Trial.
The experimental treatment LOXO-101 led to remarkable improvement for a 20-month-old girl whose rare pediatric cancer did not respond to surgery or chemotherapy.
Tumors of varied types of genetically defined cancer were significantly reduced by the drug LOXO-101, according to phase 1 study results.
Glioblastoma tumors were successfully infiltrated by investigational CAR therapy with an acceptable safety profile.
A research unit created by oncology nurses trains nurses to provide high quality care to patients in oncology clinical trials.
A clinical trial infusion nurse orientation improves training for nurses so they can better care for patients participating in investigational trials.
Cancer stem cells that drive tumor growth were halved by MEDI-551, an experimental antibody treatment for multiple myeloma, according to results of a small preliminary clinical trial.
Shortened Radiation Therapy Schedule No Worse Than Conventional Radiotherapy in Low-Risk Prostate Cancer
Treatment with a hypofractionated radiotherapy (HRT) schedule achieved similar efficacy as treatment with the longer, conventional RT (CRT) schedule in men with low-risk prostate cancer.
The addition of chemotherapy to radiation therapy prolonged survival in adults with grade 2 glial brain tumors.
The altered metabolism of methionine, tryptophan, kynurenine, and 5-methylthioadenosine can drive the development of glioblastoma. Results also suggest ways to treat the cancer, slow its growth, and precisely elucidate its extent.
The growth of medulloblastoma was inhibited by a new drug in research conducted in cell cultures and mice. This study targeted a particularly aggressive form of the disease driven by the oncogene MYC.
A next-generation immunotherapy may offer hope for treating high-grade glioma, an aggressive form of brain cancer that is notoriously hard to treat.
A new therapy might help treat a rare, high-risk cancer that begins development in the fetus or embryo, neuroblastoma, according to recent results from cell culture experiments.
Adding panobinostat to radiotherapy appears safe, tolerable, and has preliminary efficacy for treating recurrent high-grade gliomas.
The social media platform Twitter could develop into a useful tool for communicating with the public about cancer clinical trials and for recruiting participants.
Bevacizumab plus irinotecan significantly improved the 6-month progression-free survival (PFS) rate and median progression-free survival.
Combination therapy with durvalumab and tremelimumab demonstrated antitumor activity in 23% of 102 patients with lung cancer in a phase 1b trial, and toxicity was manageable.
This technique, which does not use pharmaceutical sedatives, can ease the perioperative discomfort and anxiety experienced by some patients undergoing fully awake craniotomy to remove glioma.
No evidence that interferon is necessary or helpful in cases of melanoma with minimal metastasis to the lymph nodes, according to the final results of the Sunbelt Melanoma Trial.
Detailed new information about diffuse glioma has come from an international collaborative study, raising hopes for improved clinical outcomes from a better understanding of the disease.
A past history of psychiatric disorders has been linked to suicidal ideation in patients with brain tumors.
New genetic testing can assist brain cancer treatment planning.
Treating medulloblastoma with proton beam therapy results in survival rates in line with other proton therapies, according to recent study data.
Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors.
Phase 2 trial data showed acceptable toxicity and similar survival as conventional radiotherapy for childhood medulloblastoma.
Optical probes that make cancer cells glow and improve surgical tumor removal are in phase I and II clinical trials in humans. The probes could be commonplace in the next 5 to 10 years, hypothesize the researchers.
A new clinical trial aims to apply advanced image analysis techniques to 4D CT scans. Already a standard step in targeting lung cancer radiotherapy, the trial seeks to use the scans map areas of lung function without additional testing.
Valproic acid and levetiracetam do not improve survival outcomes in patients with newly diagnosed glioblastoma, according to a recently published study.
Researchers identified characteristics that may lead to low patient accrual for a clinical trial.
Excluding patients with renal insufficiency but good performance status from clinical trials due to concern of excessive hematologic toxicity or poor outcomes may not be necessary with appropriate dosing modifications.
Mandatory tumor tissue specimens and associated analyses for clinical trial participation appear to be a significant barrier to clinical trial enrollment and may delay treatment.
New Studies Reveal Long-Term Vision-related Health Concerns of Survivors of Childhood Retinoblastoma and Brain Cancer
Two new studies investigate the impact of retinoblastoma on long-term health of survivors and the long-term psychological and socio-economic effects of blindness in survivors of brain tumors.
Progression-free and overall survival were prolonged with electromagnetic field and chemotherapy maintenance therapy in patients with a brain tumor.
A noninvasive, low-cost blood test was developed to help doctors diagnose some types of malignant childhood tumor. It could also enable treatment monitoring without exposing patients to repeated doses of radiation.
A recent study examined the efficacy of pembrolizumab for the treatment of previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
Extra biopsies performed solely to study the pharmacodynamics of a new anticancer drug have no impact on subsequent drug development or on how physicians use these new drugs to treat future patients.
Glioma Cells Self-organize Into Streams of Cells That Follow a Mathematically Predicted Pattern to Build Brain Tumors
Brain tumor cells can self-organize, according to new research. Glioma cells build tumors by self-organizing into streams 10 to 20 cells wide that obey a mathematically predicted pattern for autonomous agents flowing together.
Patient education on clinical trials prior to the first oncologic visit improves knowledge, attitudes, and preparation for decision making about clinical trials.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Comparison of Survival Outcomes Between Radical Hysterectomy and Definitive Radiochemotherapy in Stage IB1 and IIA1 Cervical Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|